Lupin Pharmaceuticals Recalls All Irbesartan and Irbesartan/HCTZ
October 14, 2021Flucelvax Quadrivalent Approved for Broader Age Group
October 15, 2021October 15, 2021 – The U.S. FDA has approved a new indication for Genentech's Tecentriq® (atezolizumab) for use as an adjuvant treatment following surgery and platinum-based chemotherapy in adults who have Stage II-IIIA non-small cell lung cancer (NSCLC) with tumors expressing PD-L1 ≥ 1%, as determined by an FDA-approved test.
- Tecentriq is now the first FDA-approved cancer immunotherapy indicated for adjuvant treatment of NSCLC. In cancer, adjuvant therapies are typically used following primary therapies such as surgery for tumor removal to reduce the risk of disease recurrence.
- First FDA approved in 2016, Tecentriq has multiple indications to treat NSCLC, and is also indicated to treat urothelial carcinoma, small cell lung cancer, hepatocellular carcinoma, and melanoma.
- Recommended dosing for adjuvant treatment of NSCLC is 840mg every two weeks, 1,200mg every three weeks, or 1,680 mg every four weeks. Treatment should continue for up to one year or until disease recurrence or unacceptable toxicity occur.
- Tecentriq is administered via intravenous infusion over the course of 60 minutes for the first infusion and, if the first infusion is tolerated, 30 minutes for subsequent infusions.